 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C14H18N2O |
| Molar mass | 230.306 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
4-HO-McPT (4-hydroxy-N-methyl-N-cyclopropyltryptamine) is a psychedelic tryptamine derivative. It has serotonergic effects, [1] and has reportedly been sold as a designer drug since around 2016, but was not definitively identified by forensic laboratories until 2018. [2] [3] It is illegal in Finland. [4]
4-Hydroxy-N,N-diisopropyltryptamine is a synthetic psychedelic drug. It is a higher homologue of psilocin, 4-HO-DET, and is a positional isomer of 4-HO-DPT and has a tryptamine molecular sub-structure.
4-HO-MiPT is a synthetic substituted aromatic compound and a lesser-known psychedelic tryptamine. It is thought to be a serotonergic psychedelic, similar to magic mushrooms, LSD and mescaline. Its molecular structure and pharmacological effects somewhat resemble those of the tryptamine psilocin, which is the primary psychoactive chemical in magic mushrooms.
Hordenine is an alkaloid of the phenethylamine class that occurs naturally in a variety of plants, taking its name from one of the most common, barley. Chemically, hordenine is the N-methyl derivative of N-methyltyramine, and the N,N-dimethyl derivative of the well-known biogenic amine tyramine, from which it is biosynthetically derived and with which it shares some pharmacological properties. As of September 2012, hordenine is widely sold as an ingredient of nutritional supplements, with the claims that it is a stimulant of the central nervous system, and has the ability to promote weight loss by enhancing metabolism. In experimental animals, given sufficiently large doses parenterally, hordenine does produce an increase in blood pressure, as well as other disturbances of the cardiovascular, respiratory, and nervous systems. These effects are generally not reproduced by oral administration of the drug in test animals, and virtually no scientific reports of the effects of hordenine in human beings have been published.
In differential calculus, there is no single uniform notation for differentiation. Instead, various notations for the derivative of a function or variable have been proposed by various mathematicians. The usefulness of each notation varies with the context, and it is sometimes advantageous to use more than one notation in a given context. The most common notations for differentiation are listed below.
Aeruginascin or N,N,N-trimethyl-4-phosphoryloxytryptamine is an indoleamine derivative which occurs naturally within the mushrooms Inocybe aeruginascens and Pholiotina cyanopus, and Psilocybe cubensis. Aeruginascin is the N-trimethyl analogue of psilocybin. It is closely related to the frog skin toxin bufotenidine (5-HTQ), a potent 5-HT3 receptor agonist, but the aeruginascin metabolite 4-HO-TMT shows strong binding at the 5-HT2 receptors similar to psilocin. The first scientific literature about the pharmacological effects of aeruginascin is from a study published by Gartz in 1989. Across 23 analyzed cases of accidental hallucinogenic mushroom poisonings, people who had ingested the mushroom Inocybe aeruginascens reported only euphoric experiences. This is in contrast to the slight and in some cases extremely dysphoric experiences reported from the accidental ingestion of non aeruginascin containing mushrooms (containing solely psilocybin and psilocin).
4-HO-MPMI (also known as 4-Hydroxy-N-methyl-(α,N-trimethylene)-tryptamine or lucigenol) is a tryptamine derivative that is a psychedelic drug. It was developed by the team led by David Nichols from Purdue University in the late 1990s. This compound produces hallucinogen-appropriate responding in animal tests with a similar potency to the amphetamine-derived psychedelic DOI, and has two enantiomers, with only the (R)-enantiomer being active.
The molecular formula C14H18N2O may refer to:
4-HO-DsBT (4-hydroxy-N,N-di-sec-butyltryptamine) is a tryptamine derivative which acts as a serotonin receptor agonist. It was first made by Alexander Shulgin and is mentioned in his book TiHKAL, but was never tested by him. However it has subsequently been tested in vitro and unlike the n-butyl and isobutyl isomers which are much weaker, the s-butyl derivative retains reasonable potency, with a similar 5-HT2A receptor affinity to MiPT but better selectivity over the 5-HT1A and 5-HT2B subtypes.
5-HO-DiPT (5-hydroxy-N,N-di-iso-propyltryptamine) is a tryptamine derivative which acts as a serotonin receptor agonist. It is primarily known as a metabolite of the better known psychoactive drug 5-MeO-DiPT, but 5-HO-DiPT has also rarely been encountered as a designer drug in its own right. Tests in vitro show 5-HO-DiPT to have high 5-HT2A affinity and good selectivity over 5-HT1A, while being more lipophilic than the related drug bufotenine (5-HO-DMT), which produces mainly peripheral effects.
5-MeO-DiBF is a psychedelic that has been sold online as a designer drug and was first definitively identified in December 2015 by a forensic laboratory in Slovenia. It is thought to act as an agonist for the 5-HT1A and 5-HT2 family of serotonin receptors. It is related in structure to the psychedelic tryptamine derivative 5-MeO-DiPT, but with the indole nitrogen replaced by oxygen, making 5-MeO-DiBF a benzofuran derivative. It is several times less potent as a serotonin agonist than 5-MeO-DiPT and with relatively more activity at 5-HT1A, but still shows strongest effects at the 5-HT2 family of receptors.
5-MeO-MALT (5-methoxy-N-methyl-N-allyltryptamine) is a lesser-known psychedelic drug that is closely related to 5-MeO-DALT and has been sold online as a designer drug.
4-HO-McPeT (4-hydroxy-N-methyl-N-cyclopentyltryptamine) is a tryptamine derivative which has serotonergic effects.
5-MeO-EPT is a psychedelic tryptamine derivative which has been sold as a designer drug.
5-MeO-MET (5-Methoxy-N-methyl-N-ethyltryptamine) is a relatively rare designer drug from the substituted tryptamine family, related to compounds such as N-methyl-N-ethyltryptamine and 5-MeO-DMT. It was first synthesised in the 1960s and was studied to a limited extent, but was first identified on the illicit market in June 2012 in Sweden. It was made illegal in Norway in 2013, and is controlled under analogue provisions in numerous other jurisdictions.
N-t-Butyltryptamine (NTBT) is a tryptamine derivative which has serotonergic effects. It is described by Alexander Shulgin as producing "a light-headed intoxication that is a totally pleasant buzz, but nothing more profound than that" at a dosage range of 5 to 20 mg, along with the related sec-butyl isomer NSBT which is similar in effects but slightly less potent.
O-Acetylbufotenine is a tryptamine derivative which produces psychedelic-appropriate responding in animal studies. It is an acylated derivative of bufotenine with higher lipophilicity that allows it to cross the blood–brain barrier; once inside the brain, it is metabolised to bufotenine. It also acts directly as an agonist at 5-HT1A and 5-HT1D receptors.
4-Hydroxy-N-propyl-N-isopropyltryptamine (4-HO-PiPT, Piprocin) is a substituted tryptamine derivative which is claimed to have psychedelic effects. It acts as a 5-HT2A receptor agonist, with an EC50 of 13.8 nM and an efficacy of 104.8% (vs 5-HT), and has been sold as a designer drug, first being identified in 2021 in British Columbia, Canada.
4-HO-MALT (4-hydroxy-N-methyl-N-allyltryptamine) is a tryptamine derivative which has been sold as a designer drug, first being detected in Slovenia in 2021.
 | This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |
